P
ProHub
English 简体中文 繁體中文
Medium M&A Capital Investment Profitability Analysis

Surgical Robot

#Medical #Healthcare #Medical Technology
ProHub Comment

This case tests financial analysis and break-even calculations, requiring candidates to evaluate capital investments against their useful life. The key insight is recognizing that while Robot X has a 20-year break-even period (unrealistic given its 10-year lifespan), the superior Da Vinci Robot performs slightly better at 7 years but still leaves minimal profit before replacement. The case effectively demonstrates how absolute numbers can be misleading without contextual analysis.

Estimated Time 15 minutes
Difficulty Medium
Source Cornell
50 / 100
Our client is a privately owned hospital that offers high-tech surgical procedures. They would like to start using robots in their surgeries. Recently, a new surgical robot, Robot X, was developed and has now been on the market for six months. This robot is highly precise and drastically reduces human work in surgeries. Should our client acquire Robot X?

Clarifying Information

  1. Our client specializes in minimally invasive surgeries, but has never employed a full robot
  2. There are currently only a few surgical robots on the market; the Da Vinci Robot is the leader in the market
  3. Of the hospital staff who are authorized to perform surgeries, 70% are technicians (with Bachelor’s degree) and 30% are medical professionals (with M.D.)
  4. Buying a surgical robot will allow our client to hire 5 fewer staff technicians per year
  5. Each staff technician is paid an annual salary of $60,000
  6. The hospital generates an extra $300/surgery that a surgical robot performs
  7. Technology replacement rate is ~10 years for surgical robots